| Literature DB >> 33324656 |
Yuko Ogawa1, Yuka Okinaka1, Yukiko Takeuchi1, Orie Saino1, Akie Kikuchi-Taura1, Akihiko Taguchi1.
Abstract
There is no effective treatment for chronic stroke if the acute or subacute phase is missed. Rehabilitation alone cannot easily achieve a dramatic recovery in function. In contrast to significant therapeutic effects of bone marrow mononuclear cells (BM-MNC) transplantation for acute stroke, mild and non-significant effects have been shown for chronic stroke. In this study, we have evaluated the effect of a combination of BM-MNC transplantation and neurological function training in chronic stroke. The effect of BM-MNC on neurological functional was tested four weeks after permanent middle cerebral artery occlusion (MCAO) insult in mice. BM-MNC (1 × 105cells in 100 μl PBS) were injected into the vein of MCAO model mice, followed by behavioral tests as functional evaluations. Interestingly, there was a significant therapeutic effect of BM-MNC only when repeated training was performed. This suggested that cell therapy alone was not sufficient for chronic stroke treatment; however, training with cell therapy was effective. The combination of these differently targeted therapies provided a significant benefit in the chronic stroke mouse model. Therefore, targeted cell therapy via BM-MNC transplantation with appropriate training presents a promising novel therapeutic option for patients in the chronic stroke period.Entities:
Keywords: bone marrow mononuclear cell; cell therapy; cerebral infarction; chronic; stroke
Year: 2020 PMID: 33324656 PMCID: PMC7726263 DOI: 10.3389/fmed.2020.535902
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Experimental design. Experimental schedule in this study. MCAO, middle cerebral artery occlusion; BM-MNC, bone marrow mononuclear cells; SCID, severe combined immunodeficiency CB-17/lcr-scid/scidJcl.
Figure 2Effect of BM-MNC transplantation at the chronic stroke phase before and after training. (A) To assess short-and long-term memory, passive avoidance was used at before the treatment, and 2 weeks after BM-MNC treatment. The latency to enter the dark compartment was measured. The BM-MNC group showed a tendency to a similar latency when compared with the no-surgery group. No significant difference was observed between PBS and BM-MNC-treated mice. (B) Neuromuscular function was measured using the wire hang test at before, and 2 and 8 weeks after cell therapy. The latency to fall was measured, and the graph shows the time series variation for this test. No difference was observed between PBS and BM-MNC treated MCAO groups before treatment; however, the latency to fall of BM-MNC treated group at 8 weeks after treatment was similar to the no-surgery mice and significantly longer when compared with the PBS treated mice. (C) Water maze test was performed at 4 weeks after the treatment. Time until mice reached a submerged platform was measured for five consecutive days. The mean latency to platform for each day over five sessions is presented. (D) Sensorimotor skills were evaluated in the rotarod test. Rotarod performance was defined as the length of time on the rotarod. This rotarod test was performed twice, days 1 and 4 at 8 weeks after treatment. Five minutes of training was conducted daily between the first and second trials. No significant difference was observed between PBS and BM-MNC treated mice; however, 3-days' training significantly improved rotarod performance in the BM-MNC-treated mice; there was a significant difference between the PBS and BM-MNC-treated group. MCAO means permanent middle cerebral artery occlusion model. MCAO + PBS; PBS administration (non-treated) model group, MCAO + BM-MNC; BM-MNC treatment model group. * means no-surgery control vs. MCAO + PBS or MCAO + BM-MNC. ‡ means MCAO + PBS vs. MCAO + BM-MNC. *‡p < 0.05.